Emmaus Life Sciences, Inc.

Equities

EMMA

US29137T1016

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 11:54:52 2024-05-16 EDT			5-day change	1st Jan Change
0.1062 ^USD	+3.16%		+1.24%	+6.19%

02-02	Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder)	CI
2023	Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5M	MT

An unknown buyer acquired 0.34% stake in CellSeed Inc. from Emmaus Life Sciences, Inc. for $0.22 million.

August 13, 2019

An unknown buyer acquired 0.34% stake in CellSeed Inc. (JASDAQ:7776) from Emmaus Life Sciences, Inc. (NasdaqCM:EMMA) for $0.22 million in June 2019.

An unknown buyer completed the acquisition of 0.34% stake in CellSeed Inc. (JASDAQ:7776) from Emmaus Life Sciences, Inc. (NasdaqCM:EMMA) in June 2019.

Latest news about Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder)	02-02	CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5M	11-14	MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Emmaus Life Sciences, Inc. Announces Board Changes	23-10-04	CI
Emmaus Life Sciences, Inc. Announces Yutaka Niihara No Longer Serve as Chief Executive Officer	23-08-23	CI
Emmaus Life Sciences, Inc. Announces Management Changes	23-08-23	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Emmaus Life Sciences, Inc Receives Marketing Authorization for EndariÂ® in Oman	23-07-13	CI
Emmaus Life Sciences, Inc. Receives Medicine Registration Certificate from the Bahrain National Health Regulatory Authority	23-05-31	CI
Emmaus Life Sciences, Inc. Receives Medicine Registration Certificate from the Bahrain National Health Regulatory Authority	23-05-31	CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q1 Revenue $6.8M	23-05-15	MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Emmaus Life Sciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Emmaus Life Sciences, Inc. Receives Kuwaiti Marketing Authorization	22-12-07	CI
Emmaus Life Sciences, Inc. Receives Endari Marketing Authorization from the Qatar Ministry of Public Health	22-11-17	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Emmaus Life Sciences, Inc. Announces Board Changes	22-10-06	CI
Emmaus Life Sciences, Inc. Announces Resignation of Masaharu Osato as Member of the Board of Director	22-09-30	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Emmaus Life Sciences, Inc. Announces Resignation of Robert Dickey IV as Director	22-08-10	CI
Emmaus Life Sciences, Inc. Announces Resignation of Executives	22-06-10	CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q1 Revenue $3.2M	22-05-13	MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI

Chart Emmaus Life Sciences, Inc.

Duration

Period

More charts

Company Profile

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing, and sale of treatments and therapies, primarily for rare and orphan diseases. The Companyâs lead product, Endari (prescription-grade L-glutamine oral powder), helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients aged five years and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainosâs IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. It has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EMMAUS LIFE SCIENCES, INC.	+6.19%	6.58M
MODERNA, INC.	+33.45%	49.46B
IQVIA HOLDINGS INC.	+1.79%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.69%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.80%	18.64B
BIO-TECHNE CORPORATION	+7.88%	13.16B
MEDPACE HOLDINGS, INC.	+29.65%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.58%	12.1B

Other Biotechnology & Medical Research